Marksans Pharma Limited — Updates, 28-04-2025: Press Release

A USFDA inspection was conducted at Time-Cap Laboratories, Inc., Marksans Pharma's wholly owned subsidiary, from 16th to 24th April 2025. The inspection yielded one observation documented in a Form 483, with no data integrity issues noted. The subsidiary is committed to addressing the observation promptly in compliance with USFDA guidelines. This development underscores the company's ongoing focus on maintaining high manufacturing standards, which could bolster its reputation and operational continuity in the competitive pharmaceutical landscape. Investors should monitor this situation closely, as timely resolution of the observation could enhance operational stability and maintain regulatory compliance.